MXCT - NASDAQ
MaxCyte, Inc.
$1.23
+1.9%MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
At a Glance
Live Snapshotmxct
Cash at End of Period
Last Annual Value
20.07M
3-Year CAGR
22%
5-Year CAGR
1%
10-Year CAGR
24%
MaxCyte, Inc. Competitors Analysis of Cash at End of Period
| Company | Cash at End of Period | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
MaxCyte, Inc. NASDAQ:MXCT | 20.07M | -24.4% | -15.9% | 5.5% | |
 Perspective Therapeutics, Inc. AMEX:CATX | 30.63M | 48.1% | -11.4% | 17.8% | |
 Atlantic International Corp. NASDAQ:ATLN | 81.13K | -60.9% | -54.2% | -9.0% | |
 Forte Biosciences, Inc. NASDAQ:FBRX | 76.96M | 27.5% | 12.9% | 30.2% | |
 Hyperfine, Inc. NASDAQ:HYPR | 36.04M | -22.0% | -28.4% | N/A | |
 Rapid Micro Biosystems, Inc. NASDAQ:RPID | 20.31M | -6.1% | -35.3% | N/A | |
 Sight Sciences, Inc. NASDAQ:SGHT | 92.23M | -12.6% | -18.8% | N/A | |
 TriSalus Life Sciences, Inc. NASDAQ:TLSI | 20.79M | 19.7% | -7.3% | N/A | |
 Owlet, Inc. NYSE:OWLT | 41.01M | 35.3% | -15.5% | N/A | |
 Armata Pharmaceuticals, Inc. AMEX:ARMP | 14.08M | -9.9% | 4.2% | 9.4% | |
 LENSAR, Inc. NASDAQ:LNSR | 12.97M | -14.3% | -16.3% | N/A |
MaxCyte, Inc. Fair Value Envelope
Related Guides
Continue your MXCT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.